A new approach to drug therapy in non-alcoholic steatohepatitis (NASH).
Liver steatosis is a common human disease, most often caused by long-term alcohol consumption. Non-alcoholic steatohepatitis (NASH) is characterized by similar histopathological features to those observed in alcoholic liver disease, but occurs in the absence of significant alcohol consumption. Several aetiological factors contribute to NASH: obesity, type 2 diabetes mellitus, hyperlipidaemia, pregnancy, different chemical intoxications, parenteral nutrition, jejeuno-ileal bypass, chronic inflammatory bowel disease, nutritional protein deficiency and congenital metabolic disorders. Biochemically, oxidative stress and lipid peroxidation and their ensuing damage are implicated in the pathogenesis of NASH and alcoholic steatohepatitis (probably resulting from free fatty acids in the mitochondria, and induction of the cytochrome P450 isoform CYP2E1 in hepatocytes and Kupffer's cells). This paper deals with the pathomechanisms, clinical findings and currently available therapies for NASH. The potential use of metadoxine in the treatment of NASH is also discussed.
Fehér
J
J
Second Department of Medicine, Medical Faculty, Semmelweis University, Budapest, Hungary. feher@bel2.sote.hu
Lengyel
G
G
D000975:Antioxidants / Q000627:therapeutic use; D004338:Drug Combinations; D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology / Q000378:metabolism; D011736:Pyridoxine / Q000627:therapeutic use*; D011761:Pyrrolidonecarboxylic Acid / Q000627:therapeutic use*
D000975:Antioxidants; D004338:Drug Combinations; C037845:metadoxine; D011736:Pyridoxine; D011761:Pyrrolidonecarboxylic Acid